5218
J. M. Bueno et al. / Bioorg. Med. Chem. Lett. 21 (2011) 5214–5218
10. Yeates, C. L.; Batchelor, J. F.; Capon, E. C.; Cheesman, N. J.; Fry, M.; Hudson, A. T.;
Pudney, M.; Trimming, H.; Woolven, J.; Bueno, J. M.; Chicharro, J.; Fernández,
E.; Fiandor, J. M.; Gargallo-Viola, D.; Gómez de las Heras, F.; Herreros, E.; León,
M. L. J. Med. Chem. 2008, 51, 2845.
11. Waiver of in vivo bioavailability and bioequivalence studies for immediate
release solid oral dosage form based on a biopharmaceutics classification
12. Xiang, H.; Surdy-Freed, J.; Moorthy, G. S.; Hugger, E.; Bambal, R.; Han, C.; Ferrer,
S.; Gargallo-Viola, D.; Davis, C. B. J. Pharm. Sci. 2006, 95, 2657.
13. Bueno, J. M. GlaxoSmithKline Laboratories, Unpublished Results.
14. Eaton, P. E.; Carlson, G. R.; Lee, J. T. J. Org. Chem. 1973, 38, 4071.
15. For experimental details: Bueno, J. M.; Chicharro, J.; Lorenzo, M.; Manzano, P.
WO2007138048, in PCT Int Appl. 2007.
antimalarial activity in vitro when it is located at position C2 in
comparison with its non hydroxylated counterpart, it is possible
to obtain potent derivatives with improved solubility and pharma-
cokinetic properties by introducing the CH2OH group at position
C6 of the 4-pyridone ring. This behaviour offers new opportunities
in the design of novel potent, more soluble and bioavailable anti-
malarial 4-pyridones.
Acknowledgement
16. Tilstam, U.; Winmann, H. Org. Proc. Res. Dev. 2002, 6, 384.
17. Liu, D. Z.; Piyamongkol, S.; Liu, D. Y.; Khodr, H. H.; Lu, S. L.; Hider, R. C. Bioorg.
Med. Chem. 2001, 9, 563.
We wish to thank MMV (Medicines for Malaria Venture) for
financial support.
18. Pankiewicz, K. W.; Nawrot, B. C.; Watanaba, K. A. J. Org. Chem. 1986, 51, 1525.
19. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Antimicrob. Agents
Chemother. 1979, 16, 710.
References and notes
20. Lavandera, J. L. GlaxoSmithKline Laboratories, unpublished work.
21. Chemical Computing Group, 1010 Sherbrooke St., West, Suite 910, Montreal
Quebec, Canada H3A 2R7.
22. CCDC, The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge
CB2 1EZ, UK.
23. Valko, K.; Du, C. M.; Bevan, Ch.; Reynolds, D. P.; Abraham, M. H. Curr. Med.
Chem. 2001, 8, 1137.
24. Avdeef, A. Curr. Top. Med. Chem. 2001, 1, 277.
25. Dressman, J. B.; Reppas, Ch. Eur. J. Pharm. Sci. 2000, 11, S73.
26. Raevsky, O. A. Mini-Rev. Med. Chem. 2004, 4, 1041.
27. Jiménez-Díaz, M. B.; Mulet, T.; Viera, S.; Gómez, V.; Garuti, H.; Ibáñez, J.;
Álvarez-Doval, A.; Shultz, L. D.; Martínez, A.; Gargallo-Viola, D.; Angulo-
Barturen, I. Antimicrob. Agents Chemother. 2009, 53, 4533.
2. Wells, T. N.; Poll, E. M. Discov. Med. 2010, 9, 389.
3. Olliaro, P.; Wells, T. N. Clin. Pharmacol. Ther. 2009, 85, 584.
4. Dondorp, A. M.; Yeung, S.; White, L.; Nguon, C.; Day, N. P.; Socheat, D.; von
Sidlein, L. Nat. Rev. Microbiol. 2010, 8, 272.
5. Slichtzer, M.; Ortmann, R. ChemMedChem 2010, 5, 1837.
6. Burrows, J. N.; Waterson, D. Discovery New Medicines to Control and Eradicate
Malaria In Trop. Med. Chem. doi:10.1007/7355_2011_14, Springer-Verlag:
Berlin-Heidelberg; 2011.
7. Rodrigues, T.; Lopes, F.; Moreira, R. Curr. Med. Chem. 2010, 17, 929.
8. Mather, M. W.; Henry, K. W.; Vaidya, A. B. Curr. Drug Targets 2007, 8, 49.
9. Painter, H. J.; Morrisey, J. M.; Mather, M. W.; Vaidya, A. B. Nature 2007, 446, 88.